Eligo Bioscience news

Paris, France, Dec 2, 2021: Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to The Rockefeller University. This invention, described in patent family WO2014124226, is owned by The Rockefeller University and exclusively licensed to Eligo Bioscience. With the ruling, the USPTO canceled all claims of all five SNIPR Biome

Paris, France-based microbiome engineering company Eligo Bioscience today announced the appointment of former GlaxoSmithKline R&D Executive, Edith M Hessel, PhD, as Chief Scientific Officer. Dr. Hessel will be responsible for the strategic expansion of new therapeutic applications of Eligo’s platform technology and for the progression of Eligo’s pipeline to the clinic. Founding CSO David Bikard, PhD, and Head of the Synthetic Biology Group at the Pasteu

Paris, France – Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutic for strain-specific microbiome modulation.

Under the terms of the agreement, Eligo will receive an upfront payment and R&D funding to advance EB005, its discovery program in acne, un